Search for more clinical trials
Cisplatin With Alimta or Gemcitabine in Long Infusion for Mesothelioma
Conditions
Mesothelioma
Conditions: official terms
Mesothelioma
Study Type
Interventional
Study Phase
Phase 2
Study Design
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Intervention
Name: Gemcitabine in long infusion
Type: Procedure
Overall Status
Recruiting
Summary
This is a randomised Phase II clinical trial to assess and compare efficacy and safety profile of cisplatin and pemetrexed against cisplatin and low-dose gemcitabine in long infusion.
Detailed Description
Combination of pemetrexed and cisplatin is now considered the standard systemic treatment for mesothelioma. Three arguments against such a position are: 1. Pemetrexed in combination with cisplatin was registered for mesothelioma on the basis of superiority over cisplatin alone, a clearly suboptimal control arm; 2. Several Phase II trials of gemcitabine in standard doses or as low-dose in long infusion in combination with cisplatin have shown at least comparable activity; 3. Due to high cost, pemetrexed is not available to many patients in countries with limited health care resources. During the past five years, our research team in Ljubljana conducted a Phase II trial of low-dose gemcitabine (250 mg/m2) in 6-hours infusion and cisplatin for patients with mesothelioma. In an unselected population of patients including those in poor performance status, elderly, patients with advanced extrathoracic disease and patients in progression after previous chemotherapy, the response rate was 54%, and median survival was 16.5 months. On the basis of this favourable experience and in search of cost-effective treatment for mesothelioma, we here propose a randomised Phase II clinical trial to compare efficacy and safety profile of cisplatin and pemetrexed against cisplatin and low-dose gemcitabine in long infusion. The primary endpoints are response rate and time to progression; secondary endpoints are survival, toxicity and quality of life.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:
- histologically proven mesothelioma. While local histopathology exam is sufficient to register a patient for the trial, all biopsies will be subject to central review (please see Section 5.3.)
- no history of other malignancy; or in complete remission for > 3 years if previously treated for other malignancy;
- chemo-naive;
- performance status ≥ 70% (Karnofsky); or ECOG 0 - 2 ;
- no peripheral neuropathy grade 2 or more (common toxicity criteria - CTC, NCI), unless mechanical in origin;
- no vascular disease grade 2 or more (NCI CTC ver.3);
- hemoglobin > 100 g/L;
- neutrophils > 2.0 g/L;
- platelets > 100 x 109 /L;
- kidney function: creatinine within normal limits + ECC > 60 mL/min; or ECC > 100 mL/min;
- liver function: bilirubin < 1.25 x UNL; AST/ALT < 2 x UNL;
- cardiac compensation;
- no active infection or other serious concomitant disease;
- women are not pregnant
- patient's understanding of the disease and treatment and written informed consent.
Exclusion Criteria:
• significant medical co-morbidity
- histologically proven mesothelioma. While local histopathology exam is sufficient to register a patient for the trial, all biopsies will be subject to central review (please see Section 5.3.)
- no history of other malignancy; or in complete remission for > 3 years if previously treated for other malignancy;
- chemo-naive;
- performance status ≥ 70% (Karnofsky); or ECOG 0 - 2 ;
- no peripheral neuropathy grade 2 or more (common toxicity criteria - CTC, NCI), unless mechanical in origin;
- no vascular disease grade 2 or more (NCI CTC ver.3);
- hemoglobin > 100 g/L;
- neutrophils > 2.0 g/L;
- platelets > 100 x 109 /L;
- kidney function: creatinine within normal limits + ECC > 60 mL/min; or ECC > 100 mL/min;
- liver function: bilirubin < 1.25 x UNL; AST/ALT < 2 x UNL;
- cardiac compensation;
- no active infection or other serious concomitant disease;
- women are not pregnant
- patient's understanding of the disease and treatment and written informed consent.
Exclusion Criteria:
• significant medical co-morbidity
Location
Institute of Oncology Ljubljana
Ljubljana, Slovenia
Status: Recruiting
Contact: Viljem Kovac, MD - +386 1 5879 504 - vkovac@onko-i.si
Start Date
August 2008
Sponsors
Institute of Oncology Ljubljana
Source
Institute of Oncology Ljubljana
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page